Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1982 1
1984 1
1985 2
1986 3
1988 2
1989 5
1990 2
1991 2
1992 2
1993 3
1994 1
1995 2
1996 2
1997 4
1998 6
1999 2
2000 5
2001 5
2002 8
2003 4
2004 6
2005 2
2006 8
2007 14
2008 15
2009 16
2010 15
2011 18
2012 19
2013 21
2014 15
2015 16
2016 16
2017 14
2018 24
2019 26
2020 33
2021 21
2022 15
2023 26
2024 52
2025 93
2026 23

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

486 results

Results by year

Filters applied: . Clear all
The following terms were ignored: %, %
The following terms were not found in PubMed: 5BAuthor
Page 1
Showing results for female f%5BAuthor%5D
Your search for Remacle F%5BAuthor%5D retrieved no results
Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson's Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study.
Aldred J, Freire-Alvarez E, Amelin AV, Antonini A, Bergmans B, Bergquist F, Bouchard M, Budur K, Carroll C, Chaudhuri KR, Criswell SR, Danielsen EH, Gandor F, Jia J, Kimber TE, Mochizuki H, Robieson WZ, Spiegel AM, Standaert DG, Talapala S, Facheris MF, Fung VSC. Aldred J, et al. Neurol Ther. 2023 Dec;12(6):1937-1958. doi: 10.1007/s40120-023-00533-1. Epub 2023 Aug 26. Neurol Ther. 2023. PMID: 37632656 Free PMC article.
Secondary endpoints included changes from baseline in normalized "Off" and "On" time, percentage of patients reporting morning akinesia, Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS), Parkinson's Disease Sleep Scale-2 (PDSS-2), 39-item Parkinson's …
Secondary endpoints included changes from baseline in normalized "Off" and "On" time, percentage of patients reporting morning akinesia, Mov …
Multimodal Physical Exercise and Functional Rehabilitation Program in Oncological Patients with Cancer-Related Fatigue-A Randomized Clinical Trial.
Fernandez-Rodriguez EJ, Sanchez-Gomez C, Mendez-Sanchez R, Recio-Rodriguez JI, Puente-Gonzalez AS, Gonzalez-Sanchez J, Cruz-Hernandez JJ, Rihuete-Galve MI. Fernandez-Rodriguez EJ, et al. Int J Environ Res Public Health. 2023 Mar 10;20(6):4938. doi: 10.3390/ijerph20064938. Int J Environ Res Public Health. 2023. PMID: 36981846 Free PMC article. Clinical Trial.
The main variables studied were the dependency levels (Barthel), cancer-related fatigue (FACT-An), health-related quality of life (EuroQoL-5D), functional capacity (SPPB), and kinesiophobia (TSK-F). RESULTS: Sample size (n = 44). ...Significant differences between c …
The main variables studied were the dependency levels (Barthel), cancer-related fatigue (FACT-An), health-related quality of life (EuroQoL- …
Smartphone-Based Speech Therapy for Poststroke Dysarthria: Pilot Randomized Controlled Trial Evaluating Efficacy and Feasibility.
Kim Y, Kim M, Kim J, Song TJ. Kim Y, et al. J Med Internet Res. 2024 Apr 25;26:e56417. doi: 10.2196/56417. J Med Internet Res. 2024. PMID: 38509662 Free PMC article. Clinical Trial.
This was evidenced by improvements from baseline (F(1,30)=34.35; P<.001), between-group differences (F(1,30)=6.18; P=.02), and notable time-by-group interactions (F(1,30)=6.91; P=.01). ...Regarding quality of life, significant improvements were observed as …
This was evidenced by improvements from baseline (F(1,30)=34.35; P<.001), between-group differences (F(1,30)=6.18; P=.02), …
Patient-reported outcomes following ciltacabtagene autoleucel or standard of care in patients with lenalidomide-refractory multiple myeloma (CARTITUDE-4): results from a randomised, open-label, phase 3 trial.
Mina R, Mylin AK, Yokoyama H, Magen H, Alsdorf W, Minnema MC, Shune L, Isufi I, Harrison SJ, Shah UA, Schecter JM, Vogel M, Lendvai N, Gries KS, Katz EG, Slaughter A, Lonardi C, Gilbert J, Li Q, Deraedt W, Filho OC, Patel N, Florendo E, Karlin L, Weisel K. Mina R, et al. Lancet Haematol. 2025 Jan;12(1):e45-e56. doi: 10.1016/S2352-3026(24)00320-X. Lancet Haematol. 2025. PMID: 39756844 Free PMC article. Clinical Trial.
Secondary endpoints reported here include time to sustained worsening of symptoms (Multiple Myeloma Symptom and Impact Questionnaire [MySIm-Q]; a key secondary endpoint) and change in European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life (QoL) Questio …
Secondary endpoints reported here include time to sustained worsening of symptoms (Multiple Myeloma Symptom and Impact Questionnaire [MySIm- …
Flexible Ureteroscopy with a Flexible and Navigable Suction Ureteral Access Sheath Versus Mini-Percutaneous Nephrolithotomy for Treatment of 2-3 cm Renal Stones: An International, Multicenter, Randomized, Noninferiority Trial.
Zeng G, Jiang K, Liu S, Wu R, Duan X, Chai CA, Gökce Mİ, Gadzhiev N, Kalathia J, Wang K, Zhao E, Song R, Kei Yuen SK, Gauhar V, Teoh JYC, Ma J, Zhang G, Zhu X, Jiang S, Wang Q, Zhang L, Hua Y, Du J, Bai S, Li X, Li Z, Zhong W, Zhao Z, Liu Y, Cao J, Zhu W. Zeng G, et al. Eur Urol. 2026 Jan;89(1):45-54. doi: 10.1016/j.eururo.2025.06.001. Epub 2025 Jun 17. Eur Urol. 2026. PMID: 40533283 Clinical Trial.
Patients with 2-3 cm stones were randomized 1:1 to FANS f-URS or mPCNL. The primary outcome was the immediate stone-free rate (SFR) (noninferiority margin -8%). ...These findings support FANS f-URS as a viable alternative to mPCNL for 2-3 cm stones....
Patients with 2-3 cm stones were randomized 1:1 to FANS f-URS or mPCNL. The primary outcome was the immediate stone-free rate (SFR) ( …
Virtual Reality for Upper Limb Rehabilitation in Subacute and Chronic Stroke: A Randomized Controlled Trial.
Kiper P, Szczudlik A, Agostini M, Opara J, Nowobilski R, Ventura L, Tonin P, Turolla A. Kiper P, et al. Arch Phys Med Rehabil. 2018 May;99(5):834-842.e4. doi: 10.1016/j.apmr.2018.01.023. Epub 2018 Feb 14. Arch Phys Med Rehabil. 2018. PMID: 29453980 Clinical Trial.
INTERVENTIONS: The experimental treatment was based on the combination of RFVE with CR, whereas control treatment was based on the same amount of CR. Both treatments lasted 2 hours daily, 5d/wk, for 4 weeks. MAIN OUTCOME MEASURES: Fugl-Meyer upper extremity scale (F …
INTERVENTIONS: The experimental treatment was based on the combination of RFVE with CR, whereas control treatment was based on the same amou …
Patient-reported outcomes from DESTINY-Breast04: trastuzumab deruxtecan versus physician's choice of chemotherapy in patients with HER2-low mBC.
Ueno NT, Cottone F, Dunton K, Jacot W, Yamashita T, Sohn J, Tokunaga E, Prat A, Tsurutani J, Park YH, Rugo HS, Xu B, Cardoso F, Mitri Z, Mahtani R, Aguilar CO, Xiao F, Harbeck N, Cameron DA, Modi S. Ueno NT, et al. Oncologist. 2025 May 8;30(5):oyaf048. doi: 10.1093/oncolo/oyaf048. Oncologist. 2025. PMID: 40349139 Free PMC article. Clinical Trial.
Change from baseline and time to definitive deterioration (TDD) were calculated from the EORTC QLQ-C30 and QLQ-BR45 and the EQ-5D-5L questionnaires. RESULTS: Baseline global health status/quality of life (GHS/QoL) scores were similar between groups (T-DXd, 331 patients; ph …
Change from baseline and time to definitive deterioration (TDD) were calculated from the EORTC QLQ-C30 and QLQ-BR45 and the EQ-5D-5L …
Sarilumab in relapsing polymyalgia rheumatica: patient-reported outcomes from a phase 3, double-blind, randomised controlled trial.
Strand V, Msihid J, Sloane J, Nivens MC, Chao J, Giannelou A, Fiore S, Araujo L, Dasgupta B. Strand V, et al. Lancet Rheumatol. 2025 Aug;7(8):e544-e553. doi: 10.1016/S2665-9913(25)00041-4. Epub 2025 Jun 19. Lancet Rheumatol. 2025. PMID: 40544861 Clinical Trial.
The patient-reported outcomes measured were Health Assessment Questionnaire Disability Index (HAQ-DI), Patient Global Assessment of Health Visual Analog Scale (VAS), Pain VAS, Short Form Health Survey (SF-36 v2), EuroQoL 5-Dimensions 3-Levels (EQ-5D including the descripti …
The patient-reported outcomes measured were Health Assessment Questionnaire Disability Index (HAQ-DI), Patient Global Assessment of Health V …
Improvements in health-related quality of life in patients with transfusion-dependent β-thalassemia after exagamglogene autotemcel.
Fuente J, Frangoul H, Lang P, Wall D, Meisel R, Corbacioglu S, Li AM, Shah AJ, Carpenter B, Kwiatkowski JL, Mapara MY, Liem RI, Rupprecht J, Kuo KHM, Merkeley H, Algeri M, Smith W, Kohli P, Li N, Rubin J, Zhang S, Hobbs W, Locatelli F. Fuente J, et al. Blood Adv. 2025 Dec 23;9(24):6502-6510. doi: 10.1182/bloodadvances.2025016702. Blood Adv. 2025. PMID: 40862696 Free PMC article. Clinical Trial.
In adults, PRO measures included the EuroQol Quality of Life Scale-5 dimensions-5 levels of severity (EQ-5D-5L) and the Functional Assessment of Cancer Therapy Bone Marrow Transplant (FACT-BMT). In adolescents, the EuroQol Quality of Life Scale-5 dimensions-youth (EQ-5D …
In adults, PRO measures included the EuroQol Quality of Life Scale-5 dimensions-5 levels of severity (EQ-5D-5L) and the Functional As …
486 results